Abstract SARS-CoV-2, the causative agent of COVID-19, primarily affects the epithelial
compartment in the upper and lower airways. There is evidence that the microvasculature in …

Understanding of human brain development, dysfunction and neurological diseases has
remained limited and challenging due to inability to recapitulate human brain-specific …

Background Although mainly causing a respiratory syndrome, numerous neurological
symptoms have been identified following of SARS-CoV-2 infection. However, how the virus …

Pathology studies of SARS-CoV-2 Omicron variants of concern (VOC) are challenged by the
lack of pathogenic animal models. While Omicron BA. 1 and BA. 2 replicate in K18-hACE2 …

Anosmia was identified as a hallmark of COVID-19 early in the pandemic, however, with the
emergence of variants of concern, the clinical profile induced by SARS-CoV-2 infection has …

In vitro models of the human blood–brain barrier (BBB) are increasingly used to develop
therapeutics that can cross the BBB for treating diseases of the central nervous system. Here …

Consistent with well-established biochemical properties of coronaviruses, sialylated glycan
attachments between SARS-CoV-2 spike protein (SP) and host cells are key to the virus's …

Anti-glial fibrillary acidic protein (GFAP) meningoencephalomyelitis (autoimmune GFAP
astrocytopathy) is a new autoimmune central nervous system (CNS) disease diagnosable by …

Parkinson's disease (PD) is a prevalent neurodegenerative disorder that affects 7-10 million
individuals worldwide. A common early symptom of PD is olfactory dysfunction (OD), and …

In this comprehensive review, we will dissect the impact of research on proteoglycans
focusing on recent developments involved in their synthesis, degradation, and interactions …